Bilateral Orchidectomy (Surgical Castration) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bilateral orchidectomy — also called surgical castration or bilateral orchiectomy — is the surgical removal of both testicles to achieve rapid, permanent, and irreversible suppression of testosterone production. The testicles produce approximately 90–95% of circulating testosterone; their removal lowers serum testosterone to castrate levels (<0.5 ng/mL, <1.7 nmol/L) within 3–12 hours of surgery — substantially faster than pharmacological methods.

The procedure has been a cornerstone of androgen deprivation therapy (ADT) for advanced and metastatic prostate cancer since Charles Huggins first demonstrated in 1941 that prostate cancer growth is androgen-dependent (Nobel Prize in Physiology or Medicine, 1966). Today, bilateral orchidectomy remains the fastest, most reliable, and most cost-effective method of castration, and is considered the reference standard against which all pharmacological ADT agents are benchmarked.

Two surgical variants are performed:

• Simple bilateral orchidectomy: Complete removal of both testicles through a scrotal incision. The spermatic cord is ligated and divided at the level of the external inguinal ring. The scrotum is left intact, often accepting prosthetic implants.
• Subcapsular bilateral orchidectomy: The testicular parenchyma (testosterone-producing Leydig cells) is surgically evacuated while the tunica albuginea (outer shell) and epididymis are preserved, maintaining scrotal volume and shape. Testosterone suppression is equivalent to simple orchidectomy. Preferred by some patients for psychological and cosmetic reasons, although the procedure is technically more demanding and carries a small risk of incomplete resection.

Despite its proven efficacy and cost advantages, bilateral orchidectomy has declined in use in high-income countries over the past two decades as LHRH agonists and antagonists became widely available. However, it remains the most commonly used form of ADT globally in resource-limited settings, and is regaining consideration in specific clinical contexts where immediate testosterone suppression is critical — for example, in spinal cord compression from vertebral metastases or severe obstructive uropathy.

Bilateral orchidectomy is primarily used in the management of prostate cancer and is occasionally employed in other clinical situations requiring testosterone elimination:

• Metastatic hormone-sensitive prostate cancer (mHSPC): The primary and most common indication. Bilateral orchidectomy provides rapid castration in men with newly diagnosed metastatic disease, particularly those with high-volume metastatic burden, impending complications (cord compression, ureteric obstruction, bone pain), or when rapid ADT initiation is clinically urgent.
• Biochemical recurrence after definitive therapy: Men with rising PSA after radical prostatectomy or radiotherapy who require ADT may opt for bilateral orchidectomy, particularly if long-term or permanent ADT is anticipated and pharmacological compliance is a concern.
• Locally advanced prostate cancer: Combined with radical radiotherapy or as neoadjuvant/adjuvant ADT for high-risk localised disease (T3, Gleason 8–10, PSA >20), where long-course ADT (18–36 months) is required. Bilateral orchidectomy avoids the compliance challenges and injection schedule of pharmacological ADT.
• Castration-resistant prostate cancer (CRPC): Even after the development of castration resistance, maintaining castrate testosterone levels (<0.5 ng/mL) remains important because androgen receptor signalling continues to drive tumour growth in most CRPC. Bilateral orchidectomy provides permanent castration, ensuring testosterone suppression is maintained without reliance on continued pharmacotherapy.
• Transitional circumstances: Occasionally performed in transgender women (male-to-female gender-affirming surgery), though this represents a distinct clinical and surgical context from oncological orchidectomy.

Bilateral orchidectomy is not indicated for localised, low- or intermediate-risk prostate cancer managed with active surveillance or curative-intent monotherapy, where ADT is not a component of standard treatment. It is also not appropriate for the management of testicular torsion or other acute scrotal conditions, which require organ-preserving exploration rather than orchidectomy.

Bilateral orchidectomy is suitable for any man requiring long-term or permanent testosterone suppression, but individual eligibility and preference require careful discussion in an oncology or urology multidisciplinary team setting.

Clinical eligibility criteria:

• Confirmed prostate cancer with an established indication for ADT (metastatic disease, high-risk locally advanced disease with planned RT, BCR requiring systemic treatment, or symptomatic disease requiring urgent castration).
• Fitness for minor surgical procedure under general, spinal, or local anaesthesia. The procedure carries minimal cardiovascular, respiratory, or wound complication risk and is suitable for elderly and frail patients who cannot tolerate major surgery.
• Patient preference for permanent castration: Because bilateral orchidectomy is irreversible, it is most appropriate for men who accept permanent testosterone suppression — either because their prostate cancer requires indefinite ADT, or because the permanence offers freedom from injection schedules, compliance concerns, and ongoing medication costs.

Special considerations:

• Urgency of ADT: Bilateral orchidectomy is the preferred method when testosterone suppression must be achieved within hours — for example, in malignant spinal cord compression from vertebral prostate cancer metastases, where LHRH agonists cause an initial "testosterone surge" (flare) lasting 1–2 weeks that could worsen neurological symptoms. Bilateral orchidectomy avoids the testosterone flare entirely.
• Cost considerations: In settings where ongoing LHRH analogue injections (monthly or quarterly depot preparations costing USD 500–1,500 per injection) are unaffordable or inaccessible, bilateral orchidectomy offers a single one-time surgical cost with equivalent long-term testosterone suppression.
• Psychological readiness: Men considering bilateral orchidectomy require thorough counselling about the permanence of the procedure, impact on body image, sexual function (loss of libido, erectile dysfunction), and the physical changes of castration (testicular absence, scrotal appearance). Testicular prostheses may be offered to reduce the cosmetic and psychological impact. Psychological support and oncology nurse specialist input are recommended before the procedure.

Understanding the bilateral orchidectomy procedure alongside its pharmacological alternatives allows patients to make an informed decision about the most appropriate form of ADT for their situation.

Bilateral orchidectomy procedure:

• Performed under general, spinal, or local anaesthesia with intravenous sedation as a day-case or overnight procedure (30–60 minutes operative time).
• A transverse or vertical scrotal incision is made; the testicles are delivered, the spermatic cord is double-ligated with absorbable suture, and the testes are excised. The scrotal wound is closed in layers.
• Silicone testicular prostheses (saline-filled or solid) can be inserted into the scrotum at the same operation to maintain cosmetic appearance; not all patients choose this option.
• Return to normal activity in 1–2 weeks; sexual abstinence for 2–3 weeks post-operatively.

Pharmacological alternatives delivering equivalent testosterone suppression:

• LHRH agonists (gonadotrophin-releasing hormone agonists): Leuprolide (Lupron), goserelin (Zoladex), and triptorelin administered as subcutaneous depot injections (monthly, 3-monthly, or 6-monthly). Achieve castrate testosterone levels within 2–4 weeks, but cause an initial testosterone surge (flare) in the first 1–2 weeks — which can transiently worsen bone pain, urinary obstruction, or neurological symptoms. Co-administration of an anti-androgen (bicalutamide) for 2–4 weeks prevents flare symptoms. Reversible: testosterone recovers over 3–12 months after stopping injections (though recovery may be incomplete after prolonged use).
• LHRH antagonists (GnRH antagonists): Degarelix (Firmagon — monthly subcutaneous injection) and relugolix (Orgovyx — daily oral tablet) suppress testosterone without an initial testosterone surge — reaching castrate levels within 3 days. Equivalent testosterone suppression to orchidectomy or LHRH agonists. Relugolix (HERO trial) demonstrated faster testosterone suppression, faster testosterone recovery after discontinuation, and significantly lower rates of major adverse cardiovascular events (MACE) compared to leuprolide — an important advantage in men with cardiovascular comorbidity. Reversible upon discontinuation.
• Combined androgen blockade (CAB): Addition of a first-generation anti-androgen (bicalutamide, flutamide) to LHRH agonist or orchidectomy blocks adrenal androgen contribution (~5% of circulating androgens). Meta-analyses show a modest 2–3% improvement in 5-year survival over castration alone; rarely standard practice outside specific clinical contexts.

Bilateral orchidectomy offers several distinct advantages over pharmacological forms of androgen deprivation therapy:

• Immediate testosterone suppression: Serum testosterone falls to castrate levels (<0.5 ng/mL) within 3–12 hours of surgery — faster than any pharmacological agent. This is critical in oncological emergencies such as malignant spinal cord compression or severe obstructive uropathy from metastatic prostate cancer, where delayed testosterone suppression could result in irreversible neurological damage or renal failure.
• No testosterone surge (flare): Unlike LHRH agonists, bilateral orchidectomy does not cause an initial testosterone surge. This is particularly important in patients with vertebral metastases at risk of cord compression, extensive bone disease, or obstructive uropathy — conditions in which a transient testosterone flare could precipitate life-threatening complications.
• Permanent and reliable suppression: Once performed, testosterone is permanently suppressed without dependence on patient compliance, injection scheduling, drug supply chains, or insurance authorisation. Serum testosterone is consistently maintained below castrate thresholds, with no risk of subtherapeutic levels between depot injections.
• Cost-effectiveness: A single surgical procedure lasting 30–60 minutes eliminates the need for monthly or quarterly injections costing USD 500–1,500 per dose — potentially saving tens of thousands of dollars over a multi-year ADT course. In resource-limited settings, this single-time cost makes bilateral orchidectomy the most accessible form of ADT.
• Avoidance of injection-related adverse effects: Eliminates injection site reactions, subcutaneous nodules, and the logistical burden of regular clinic attendance for depot injections.
• Equivalent oncological outcomes: Prospective trials and meta-analyses confirm that bilateral orchidectomy achieves equivalent PSA response, progression-free survival, and overall survival compared to LHRH agonists in hormone-sensitive prostate cancer.

The risks of bilateral orchidectomy fall into two categories: procedural surgical risks (short-term) and physiological consequences of castration (long-term, shared with all forms of ADT).

Surgical risks (minor procedure, low complication rate):

• Scrotal haematoma: Accumulation of blood in the scrotum (1–3%); most resolve conservatively; rarely requires surgical drainage.
• Wound infection: Superficial scrotal wound infection in 1–2%; treated with antibiotics.
• Prosthesis-related complications (if inserted): Implant migration, extrusion, or infection requiring removal in <2% of cases.

Long-term physiological effects of castration (identical regardless of whether castration is surgical or pharmacological, but permanent with orchidectomy versus potentially reversible with pharmacological ADT):

• Hot flushes (vasomotor symptoms): Occur in 50–80% of men after castration; often the most bothersome side effect. Managed with medroxyprogesterone acetate (MPA), cyproterone acetate, venlafaxine, gabapentin, or acupuncture.
• Sexual dysfunction: Loss of libido is near-universal after castration; erectile dysfunction affects most men within 3–6 months. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) may help those with residual vascular function; testosterone replacement is contraindicated in prostate cancer.
• Osteoporosis: Castration significantly accelerates bone mineral density loss (2–5% per year at the hip and spine). DEXA bone density assessment at baseline and every 1–2 years; calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation; bisphosphonates (zoledronic acid) or denosumab for established osteoporosis or >10% 10-year fracture risk (FRAX score).
• Metabolic syndrome and cardiovascular risk: Castration increases fat mass, reduces lean muscle mass, increases insulin resistance, and raises LDL cholesterol — conferring a metabolic syndrome phenotype that increases cardiovascular risk over time. Regular cardiovascular screening, lifestyle modification (exercise, diet), and statin therapy where appropriate are recommended.
• Anaemia: Testosterone stimulates erythropoietin production; castration causes a mild normocytic anaemia (average haemoglobin decline of 1–2 g/dL) that typically does not require treatment.
• Body image and psychological impact: Scrotal emptiness, gynaecomastia (breast tissue development in 15–20% of men on long-term ADT), and the systemic effects of castration significantly affect body image, identity, and emotional well-being. Structured psychological support and oncology nursing input are essential components of ADT management.

Follow-up after bilateral orchidectomy addresses both oncological monitoring of prostate cancer and long-term management of the physiological consequences of castration.

Oncological surveillance:

• PSA measurement every 3–6 months: PSA nadir is typically reached within 3–6 months of castration and is a strong prognostic marker. Failure to reach PSA nadir <0.2 ng/mL on ADT suggests primary castration resistance. Rising PSA despite maintained castrate testosterone defines biochemical castration-resistant prostate cancer (bCRPC), which triggers workup (bone scan, CT, PSMA PET-CT) and escalation of treatment (enzalutamide, abiraterone, docetaxel).
• Serum testosterone measurement every 6 months to confirm maintained castrate levels (<0.5 ng/mL, <1.7 nmol/L). After bilateral orchidectomy, testosterone is expected to remain permanently suppressed without ongoing pharmacological intervention. Unexpected testosterone rise should prompt investigation for adrenal androgen excess or AR splice variant expression.
• Imaging surveillance: CT chest/abdomen/pelvis and bone scan every 6–12 months in metastatic disease; interval adjusted based on clinical response, PSA kinetics, and symptoms.

Castration side-effect monitoring:

• DEXA bone density scan at baseline, 12 months, and every 2 years thereafter; vertebral fracture assessment (VFA) in men with height loss. Zoledronic acid or denosumab prescribed for T-score <-2.5 or high 10-year fracture probability.
• Fasting glucose, HbA1c, lipid profile at baseline and annually; referral to diabetes team or cardiologist for metabolic syndrome management.
• Haemoglobin annually; anaemia symptom review at each visit.
• Breast examination and mammography if symptomatic gynaecomastia (uncommon with castration monotherapy; more common with anti-androgen monotherapy).
• Psychological and quality-of-life review at each visit using validated tools (EPIC, FACT-P). Hot flush diary, libido assessment, and referral to oncology psychologist or sexual health specialist as appropriate.

One of the most compelling arguments for bilateral orchidectomy over pharmacological ADT is its significant long-term cost advantage, particularly in settings where healthcare funding is limited or drug costs are high.

• Bilateral orchidectomy — one-time surgical cost: The procedure costs approximately USD 2,000–6,000 in the United States (day-case surgery, anaesthesia, facility fee), GBP 1,500–3,000 in the UK under NHS or privately, and USD 300–1,200 at accredited urology centres in India, Thailand, or Southeast Asia. After this single expenditure, no further cost is incurred for testosterone suppression.
• LHRH agonist comparison — ongoing medication cost: Leuprolide depot (Lupron) costs approximately USD 500–1,500 per monthly injection in the USA, or USD 3,000–6,000 for a 3-monthly depot (Lupron Depot 22.5 mg). Over a 5-year ADT course, cumulative pharmacological costs reach USD 60,000–180,000 — compared to the single surgical cost of bilateral orchidectomy. Generic leuprolide and branded alternatives are available at significantly lower prices in India, Southeast Asia, and Eastern Europe.
• GnRH antagonists — higher cost per unit: Degarelix (monthly subcutaneous injection) and relugolix (daily oral tablet) carry premium costs compared to generic leuprolide; relugolix in particular costs approximately USD 2,500–3,500 per month in the USA. These agents are primarily selected for their cardiovascular safety advantages (HERO trial) and absence of testosterone flare.
• Global cost perspective: In low- and middle-income countries where LHRH agonists are expensive or unavailable, bilateral orchidectomy remains the most accessible and cost-effective form of ADT. India, Sub-Saharan Africa, and Southeast Asia report bilateral orchidectomy rates substantially higher than comparable Western European or North American urology practices.
• Hidden costs of pharmacological ADT: Ongoing clinic visits for injections, nursing time, drug storage, refrigeration requirements, and prescription management add indirect costs to pharmacological ADT that are eliminated by surgical castration.

Several pharmacological alternatives to bilateral orchidectomy achieve equivalent or comparable testosterone suppression, each with distinct advantages and disadvantages:

• LHRH agonists (GnRH agonists): Leuprolide, goserelin, and triptorelin suppress testosterone to castrate levels within 2–4 weeks via pituitary downregulation. The main disadvantage is the initial testosterone surge (flare), managed by co-administering an anti-androgen for 2–4 weeks. Available as monthly, 3-monthly, or 6-monthly depot preparations — allowing convenient dosing. Reversible (testosterone recovery over 3–12 months after stopping), which is an advantage for men on intermittent ADT protocols or those with early disease who may discontinue therapy.
• LHRH antagonists (GnRH antagonists): Degarelix (monthly subcutaneous injection) and relugolix (daily oral tablet, HERO trial) suppress testosterone without a testosterone flare, reaching castrate levels within 3 days. Relugolix demonstrated significantly lower rates of major adverse cardiovascular events (MACE) compared to leuprolide in the HERO trial (2.9% vs 6.2%), making it the preferred pharmacological choice for men with significant cardiovascular comorbidity. Fully reversible.
• Abiraterone acetate + prednisone: A CYP17 inhibitor (abiraterone) blocks adrenal androgen synthesis more completely than castration alone. Used in combination with ADT (LHRH agonist or bilateral orchidectomy) for high-risk mHSPC (LATITUDE, STAMPEDE trials) — not an alternative to castration but an intensification added to it.
• Novel androgen receptor pathway inhibitors (ARPIs): Enzalutamide, apalutamide, and darolutamide — next-generation anti-androgens used in combination with castration for mHSPC (ARCHES, TITAN, ARASENS trials). These agents dramatically improve overall survival in combination with ADT but are not replacements for castration.
• Oestrogen therapy: Diethylstilboestrol (DES) and transdermal oestrogen (PATCH trial) suppress testosterone to castrate levels via central negative feedback and reduce LH secretion. They are an effective alternative in resource-limited settings but carry cardiovascular risks (thromboembolic events) with oral formulations; transdermal oestrogen avoids the first-pass hepatic effect and may have a more favourable cardiovascular profile.
• Intermittent ADT: Pharmacological ADT (not bilateral orchidectomy, which is permanent) can be administered intermittently — cycling treatment on and off based on PSA response — to partially preserve testosterone recovery periods, potentially reducing side effect burden and improving quality of life between cycles. Appropriate for selected patients with non-metastatic biochemical recurrence.